Pending postmarket study commitments dropping

Share this content:
The FDA says 71% (899) of pending postmarketing study commitments promised by drug sponsors at the time of approval have never been started. This is a worsening trend; in 2005, 65% (797) of pending studies had not been started.

Share this content:
Scroll down to see the next article